Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: From the bench to the clinic and back again

Article in Regenerative Medicine · May 2012
DOI: 10.2217/rme.12.12 · Source: PubMed

7 authors, including:

Joseph T Patterson
Yale University
4 PUBLICATIONS  57 CITATIONS

Mark Maxfield
Yale University
29 PUBLICATIONS  274 CITATIONS

Yuji Naito
Kitasato University
74 PUBLICATIONS  1,041 CITATIONS

Toshiharu Shinoka
The Ohio State University
213 PUBLICATIONS  5,190 CITATIONS

Available from: Toshiharu Shinoka
Retrieved on: 18 September 2016
Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again

Since the first tissue-engineered vascular graft (TEVG) was implanted in a child over a decade ago, growth in the field of vascular tissue engineering has been driven by clinical demand for improved vascular prostheses with performance and durability similar to an autologous blood vessel. Great strides were made in pediatric congenital heart surgery using the classical tissue engineering paradigm, and cell seeding of scaffolds in vitro remained the cornerstone of neotissue formation. Our second-generation bone marrow cell-seeded TEVG diverged from tissue engineering dogma with a design that induces the recipient to regenerate vascular tissue in situ. New insights suggest that neovessel development is guided by cell signals derived from both seeded cells and host inflammatory cells that infiltrate the graft. The identification of these signals and the regulatory interactions that influence cell migration, phenotype and extracellular matrix deposition during TEVG remodeling are yielding a next-generation TEVG engineered to guide neotissue regeneration without the use of seeded cells. These developments represent steady progress towards our goal of an off-the-shelf tissue-engineered vascular conduit for pediatric congenital heart surgery.

KEYWORDS: congenital heart surgery, drug-eluting scaffold, tissue-engineered vascular graft, tissue engineering, vascular graft

Single ventricle cardiac anomalies: a significant health problem

From the beginning, our efforts at translating tissue engineering technology from bench to bedside have focused on treatments for pediatric congenital heart disease (CHD). There are currently no manmade vascular conduits with growth potential, making the tissue-engineered vascular graft (TEVG) a novel technology. Great numbers of patients, including those requiring grafts for dialysis angioaccess, coronary artery bypass graft or peripheral arterial bypass surgery, stand to benefit from improvements in vascular graft technology. However, the TEVG, with its inherent capacity for somatic growth, is uniquely suited to the treatment of pediatric CHD. It is in this population that the TEVG could have the greatest impact.

According to the American Heart Association (AHA), congenital cardiovascular defects are present in approximately 1% of live births, making CHD the most common congenital malformation of newborns. CHD is the leading cause of death in the first year of life, and nearly twice as many children die from CHD in the USA each year as do from all forms of childhood cancers combined [101]. Approximately half of all infants born with CHD require surgical intervention to establish cardiovascular continuity that can support growth and prevent development of arrhythmias, developmental disorders, congestive heart failure and early death [101].

CHD can be categorized as mild, moderate or severe [1]. Between 1990 and 2000, an estimated 200,000 infants were born with severe CHD in the USA [2]. Single ventricle cardiac anomalies, a diverse group of structural anomalies that includes tricuspid atresia, pulmonary atresia and hypoplastic left heart syndrome, represent the most severe form of CHD. Surgical reconstruction of single ventricle physiology re-establishes division between pulmonary and systemic circulations, prevents premature heart failure and is essential for long-term survival [3,4]. This intervention can be accomplished in a series of staged operations referred to as the Fontan operation [5].

In the Fontan operation, venous return to the heart is routed directly to the pulmonary artery (PA), allowing deoxygenated blood to flow passively through the pulmonary circulation (Figure 1). Reoxygenated blood then returns to the single functional ventricle, where it is pumped through the systemic circulation and delivers oxygen. In the first stage of the Fontan operation (called the hemi-Fontan or Glenn operation), the superior vena cava (the great vein that returns deoxygenated blood from the upper half of the body) is directly connected (anastomosed) to the PA. In the second stage of the Fontan operation (completion Fontan, modified Fontan or extracardiac total cavopulmonary connection [EC TCPC]) the inferior vena cava (IVC), the great vein that returns deoxygenated blood from the lower half of the body to the right atrium, is also connected to the PA.
the body, is connected to the PA. This is accomplished by placing a vascular conduit between the vena cavae and the pulmonary circulation (Figure 1).

**Figure 1. Tissue-engineered vascular graft as an extracardiac total cavopulmonary connection in the modified Fontan operation.** In the treatment of single ventricle physiology, the two-stage modified Fontan diverges from the classic Glenn operation by isolating the right atrium from venous return. Venous blood is passively delivered to the right pulmonary artery. In the first stage of the operation, the SVC is anastomosed to the right pulmonary artery. After the second stage, a vascular conduit such as a TEVG connects the IVC to the right pulmonary artery. IVC: Inferior vena cava; SVC: Superior vena cava; TEVG: Tissue-engineered vascular graft.

Currently employed vascular conduits: a limiting factor in the treatment of severe CHD

The Fontan procedure was developed in the 1970s as a treatment for patients with single ventricle physiology. In the original operation, the atrium was directly connected to the PA [5,6]. The flow of blood from the IVC to the atrium and then to the PA resulted in loss of laminar flow and development of turbulence due to the size mismatch between the IVC and atrium. Since the pulmonary circulation is passive after Fontan surgery, loss of laminar flow significantly decreased the pulmonary circulation, thereby limiting its effectiveness. The original Fontan operation was associated with unacceptably high rates of morbidity and mortality [7], which encouraged further development and modification of the procedure. The modified Fontan that is most commonly performed uses an extracardiac conduit to channel blood from the IVC directly to the right PA. This EC TCPC bypasses the right atrium, thus maintaining laminar flow and increasing the flow of blood through the pulmonary circulation [8]. Outcomes are vastly improved compared with the original procedure; however, complications arising from the use of synthetic vascular grafts are a leading source of morbidity and mortality [9].

No existing vascular graft is an ideal conduit for the EC TCPC Fontan procedure. Polytetrafluoroethylene (PTFE or Gore-Tex™ [Gore-Tex Stretch Vascular Graft, WL Gore and Associates Inc., AZ, USA]) conduits, which have a lower failure rate than Dacron (Meadox woven double velour, Meadox Medicals Inc., NJ, USA) conduits [10], are currently the most widely used vascular grafts for this operation [11]. Autografts have also been used as EC TCPC conduits, but to a much more limited extent than PTFE [12]. Due to the anticipated growth of the child, oversized grafts are often needed to avoid outgrowing the conduit. When possible, surgery is delayed until the patient is between 2 and 4 years of age, at which time the diameter of the pediatric IVC approaches 60–80% of the adult IVC. This delay permits the placement of a near adult-sized conduit (20–22 mm) and limits the need for conduit replacement due to somatic growth alone. However, graft oversizing is associated with an increased risk of complications such as thrombus formation due to flow abnormalities [13]. Delaying surgery to minimize the number of reoperations can also precipitate cardiac dysfunction and heart failure from prolonged exposure to volume overload and chronic hypoxia [12,14]. Recent studies have demonstrated marked improvements in somatic growth in patients who undergo surgery at an earlier age, thus providing further support for early intervention with use of EC TCPC [15]. These findings illustrate the desirability of early intervention with an expansile conduit that can accommodate the somatic growth of the IVC.

Ultimately, thrombosis is the leading cause of graft failure and conduit replacement in the early postoperative period for synthetic conduits. The incidence of this mode of failure and conduit replacement operations could be reduced by matching graft diameter to the patient’s IVC [10]. Notably, there is a small group of patients that can benefit from the use of autologous tissue for EC TCPC. However, this is only possible in those patients with either sufficient vascular tissue to make a direct end-to-end connection between the vena cavae and the PA [16] or with sufficient pericardium to bridge these circuits.
with a pericardial roll [17]. Use of autologous tissue offers superior outcomes compared with synthetic grafts [18], but the vast majority of patients are not amenable to such reconstruction [19]. These patients would benefit from a vascular graft that is both thromboreistant and capable of growing with the patient.

Tissue engineering offers an additional strategy for constructing an autologous graft for use in patients undergoing the modified Fontan procedure. The advantages of a TEVG include decreased thrombogenicity and the ability to grow, remodel and rebuild. For more than a decade, our laboratory has been dedicated to the design, study and optimization of the TEVG. Using the classic tissue engineering paradigm of cells and scaffold [20], we have developed a TEVG for use in pediatric cardiothoracic applications that is superior to all other available synthetic vascular conduits.

**Evolution of the tissue-engineered vascular conduit: animal studies demonstrating the feasibility of large-caliber TEVGs for low-pressure, high-flow applications & our first clinical trial**

We were the first to describe the successful use of a TEVG as a PA interposition graft using tissue engineering methodology [21]. Using a lamb model, we seeded either autologous arterial or venous cells onto a biodegradable scaffold of tubularized polyglycolic acid (PGA) mesh. Cells were obtained by explanting segments of autologous artery or vein, expanding the resulting mixed cell population in culture and separating the cultures into endothelial-rich and endothelial-deficient fractions. The latter was seeded onto the scaffold and maintained in culture for 1 week. After this initial culture, the endothelial-rich fraction was seeded onto the inner lumen and maintained for an additional day. Seeded or unseeded constructs were implanted as interposition grafts replacing 2-cm sections of the main PA in juvenile lambs (n = 8). No anticoagulation therapy was used. The tissue engineered pulmonary conduits were serially monitored using echocardiography and angiography and were harvested 6 months after implantation. All seeded scaffolds were patent and demonstrated noneurymal increases in size, while unseeded scaffolds formed thrombi and stenosed within 2 weeks of implantation. Within 11 weeks, no scaffold material remained in the TEVG. Histologically, grafts showed significant collagen content (73.9% of native IVC), medial elastic fiber production and luminal endothelial-specific factor VIII-related antigen and, in addition, showed evidence of remodeling and no macroscopic calcifications. We concluded that living vascular grafts that functioned well as a PA replacements could be engineered according to classical tissue engineering techniques that TEVGs demonstrated noneurymal growth in diameter and that grafts possessed an endothelial lining and overall morphology resembling native PA [21].

In 2001, we reported our findings using a new biodegradable scaffold composed of a 50:50 copolymer of L-lactide and ε-caprolactone reinforced with nonwoven PGA fiber fabric (poly[chitosan-g-lactic acid]/PGA). Mixed cell populations obtained from explanted segments of saphenous vein were expanded in culture, seeded onto the lumen of the scaffold, and maintained in culture for 1 week before implantation as intrathoracic IVC interposition grafts in a dog model (n = 4). The TEVGs were harvested over a 6-month time course and showed no evidence of stenosis, dilatation or thromboembolic complications, even without anticoagulation therapy. Immunohistochemical staining confirmed the presence of a factor VIII antigen-positive endothelial monolayer lining the graft lumen, α-actin and desmin-expressing smooth muscle cells (SMCs) in the graft wall and a robust extracellular matrix with both collagen and elastin fibers [22].

Using this methodology, we performed the first successful clinical application of a TEVG in 1999 [23]. A 2-cm thrombosed segment of a PA was replaced with a TEVG in a 4-year-old girl who had undergone a PA angioplasty and Fontan procedure at 3 years of age. The graft was created from autologous cells obtained from a 2-cm segment of explanted peripheral vein. Vascular cells were isolated from the explant according to our established protocol [24], expanded in culture for 8 weeks and statically seeded onto a tubular scaffold fabricated from a 50:50 copolymer of ε-polycaprolactone–polylactic acid reinforced with woven PGA fibers. The biodegradable polymer conduit measured 10 mm in diameter, 20 mm in length and 1 mm in thickness and was designed to degrade over an 8-week period. A total of 10 days after seeding, the graft was implanted. The patient was maintained on intravenous heparin in the early postoperative period, followed by 5 mg/kg aspirin and warfarin for at least 3 months. No postoperative complications occurred, and on follow-up angiography, the graft was noted to be completely patent. A total of 7 months after implantation, the patient was doing well, without evidence of graft occlusion or
aneurysmal changes on chest radiography. While
this investigation clearly demonstrated the feasi-
bility of using TEVGs in congenital heart surgery,
the ultimate clinical utility of this technology was
limited by the prolonged period of time required
to expand the cells in culture. Therefore, we began
to explore the potential of using alternative cell
types and cell sources for constructing TEVGs.

Prior studies by other investigators had
demonstrated that vascular grafts seeded with
bone marrow cells (BMCs) formed an endothelial
monolayer and that autocrine signals released
by seeded BMCs contribute to endothelialization
and vasculogenesis [25]. In particular, a subset of
BMCs described as endothelial progenitor cells
homed to sites of neovascularization and differenti-
te into endothelial cells (ECs) [26]. Rapid
endothelialization is desirable because healthy
ECs reduce the immediate thrombogenicity and
immunogenicity of the TEVG and prevent early
graft occlusion [27]. Based on these observations,
we investigated the use of BMCs as a potential cell
source for vascular tissue engineering. In 2003,
we described a large animal study evaluating the
use of autologous BMCs enriched for the mono-
nuclear fraction (BM-MNCs) to create a TEVG
using our poly(chitosan-g-lactic acid)/PGA matrix [28]. Approximately 1000 autologous
BM-MNCs/mm² were statically seeded onto the
luminal surface of the scaffold and maintained in
culture for 2 h to allow for cell attachment. The
seeded constructs were then implanted as interpo-
sition grafts replacing the intrathoracic IVC in an
adult beagle model (n = 16) and harvested over a
2-year time course. All seeded grafts were patent
without evidence of thrombosis (no anticoagula-
tion was used), stenosis or aneurysm formation.

Immunohistochemical analysis demonstrated
that the seeded BM-MNCs adhered to the scaf-
dfold before implantation. Upon explantation,
we observed expression of endothelial mark-
ers in the scaffold such as CD146, factor VIII,
von Willebrand factor (vWF) and CD31, and
smooth muscle cell markers such as smooth
muscle cell-specific α-actin, SMemb, SM1 and
SM2. VEGF and Ang-1 were also produced by
the tissue engineered grafts. We concluded that
autologous BM-MNCs could be used as a practi-
cal cell source for creating TEVGs, enabling rapid
cell harvest without the need for cell culture,
and we observed that the BM-MNCs promoted
organized neotissue formation [28].

We had particular interest in using autologous
BM-MNCs as our cell source because of the intrin-
sic difficulties associated with using cells derived
from explanted venous tissue. Harvesting venous
cells requires a more invasive operative procedure
with its own inherent risks [29]. Explantation is
not always successful and sometimes fails to
produce cells for culture [30], and the ability to
harvest cells can be affected by the patient’s age
or underlying medical conditions [31]. The expan-
sion of cells in culture is time-consuming (in our
experience requiring 8–12 weeks), which limits
the availability and clinical utility of the TEVGs.
Finally, growth in culture exposes cells to various
environmental factors including media, serum and
environmental pathogens, which increases the risk
of contamination and even cellular dedifferentia-
tion [30]. These factors justified our investigation
into the use of BM-MNCs as a cell source for our
TEVG. On the basis of our animal studies, we
adapted the use of autologous BM-MNCs for the
creation of TEVGs for clinical use. Importantly,
the abundance of BM-MNCs available from a sin-
gle harvest eliminated the need for cell expansion
and permitted rapid construction of an autolo-
gous TEVG that was ready for implantation on
the same day as cell harvest. While not strictly
‘off-the-shelf’, the BMC-seeded graft represented
a leap forward in clinical utility.

Along with our investigation into this new
cell source for the TEVG, we fabricated a second
scaffold designed to degrade more slowly than
the PGA-based scaffold. The rationale for this
modification was to design a scaffold that would
provide structural support for a longer period of
time and might allow greater neotissue formation
and development. Although the degradation pro-
cess is unchanged, a poly(lactic acid)-based matrix
degrades over a 2-year time frame compared with
2 months for PGA [28].

Based on our animal experiments using
BM-MNC-seeded scaffolds, we initiated a clinici-
al trial in 2001 evaluating the use of TEVGs
and patches for congenital heart operations at the
Women’s Medical University in Tokyo, Japan
[23,28,30,32]. In 2005, we presented our midterm
clinical results of TEVGs seeded for these opera-
tions performed between 2001 and 2004 [38]. In
these operations, we obtained 4–5 ml/kg BMCs,
enriched for the mononuclear cell populations,
and seeded by manual pipetting onto poly(l-1actic acid/
poly(e-caprolactone/l-lactide) or polyglycolic acid/poly
(e-caprolactone/l-lactide) scaffolds. Seeded
scaffolds were cultured for 2–4 h intraoperatively
and then implanted. Twenty-three patients had
tube grafts as an EC TCPC implant, while the
other 19 patients had a sheet-type patch used for
repair of congenital cardiac defects. Inclusion crite-
dria for patients for this procedure were elective sur-
gery, age younger than 30 years and good quality
Tissue-engineered vascular grafts for use in the treatment of congenital heart disease

of other organ function. All patients underwent a catheterization study, CT scan or both after the operation. The patients received 3–6 months of anticoagulation therapy, consisting of warfarin sodium and aspirin, with international normalized ratio maintained between 1.5 and 2.0. After 6 months and for another 12 months, patients were maintained on aspirin alone. At midterm follow-up after surgery (average follow-up: 1.3 years), there were no complications using TEVG such as thrombosis, stenosis or obstruction. All tube grafts were patent, and the diameter of the tube graft increased with time (110 ± 7% of the implanted size). One late death at 3 months after EC TCPC occurred in a patient with hypoplastic left heart syndrome, although this was unrelated to TEVG function. There was no evidence of aneurysm formation or calcification on cineangiography or CT at the midterm analysis.

Late-term analysis (average follow-up: 5.8 years) similarly demonstrated no cases of graft-related mortality, aneurysmal dilation, graft infection, graft rupture or ectopic calcification. By contrast with Dacron and PTFE graft recipients who typically remain on long-term anticoagulation therapy [10,33,34], 96% of patients were able to discontinue anticoagulation therapy 6 months after the TEVG operation. Three patients with known cardiovascular anomalies died of causes unrelated to TEVG failure during the late-term analysis period. Notably, surveillance imaging in the months prior to death demonstrated patent TEVGs in all four deceased trial participants [35].

Further translation of this work was limited by our understanding of the processes involved in transforming a TEVG scaffold into a functional neovessel. We returned to animal models to characterize these processes and to validate the TEVG in an expanded range of applications. Early efforts to optimize BM-MNC seeding methods yielded standardized protocols for cell concentration and culture time [36], as well as an operator-independent vacuum seeding technique that replaces manual pipette-based seeding and achieves a far more consistent seeding pattern [37]. These standardizations and the validation thereof in large animal models [36] paved the way for the first US FDA-sanctioned clinical trial of a TEVG for a pediatric cardiothoracic application in the USA (Figure 2) [102].

**Next-generation TEVG: investigating the molecular mechanisms of neotissue formation**

In the Japanese clinical trial and consistently in our animal models, the primary graft-related complication is late asymptomatic stenosis observed 6 months after implantation [35,36]. Graft stenosis in our human trials has been discovered on surveillance imaging in 16% of patients and managed pre-emptively by percutaneous angioplasty. Mural thrombi are infrequent causes of postoperative graft failure and are reversible if managed appropriately by anticoagulation therapy. Aneurysm formation, graft rupture, graft infection or ectopic calcification have not been observed.

The observation of graft stenosis led us to investigate in detail the cellular and molecular mechanisms of neotissue formation in our TEVG, as well as the mechanisms of aberrant signaling that precipitate TEVG stenosis. In 2008, we described the development of mouse models of aortic and IVC replacement [38]. A dual-chamber molding system allowed us to reproducibly fabricate PGA-P(CL/LA) and PLLA-P(CL/LA) scaffolds with a sub-1-mm internal diameter, which is well below the lower size limit of clinical utility for Dacron and PTFE vascular prostheses with or without cell seeding [39]. We implanted unseeded TEVG scaffolds as infrarenal aortic or IVC interposition grafts in SCID/bg mice without the use of peri- or postoperative anticoagulation or antiplatelet therapy. Grafts were explanted at week 3 and later demonstrated typical foreign body innate immune reactions to the scaffold [40], with predominant macrophage infiltration and foreign body giant cell formation. Explanted grafts were completely infiltrated with cells and extracellular matrix organized in a prototypical three-layer vascular architecture with vWF⁺ endothelization at the luminal surface, a mural α-SMA-expressing media layer and collagenous adventitia [38].

We then implanted small-diameter PLLA-P(CL/LA) scaffolds seeded with terminally differentiated human vascular cells in immunodeficient mice to characterize the mechanisms by which stenotic failure occurs in our tissue-engineered constructs. These studies illuminated the influence of cell seeding on the development of TEVG stenosis. Human aortic smooth muscle cells (hASMCs) and human aortic ECs (hAECs) were labeled with ultrasmall superparamagnetic iron oxide nanoparticles to enable magnetic resonance cell tracking. Near-total loss of seeded hASMCs and hAECs from PLLA-P(CL/LA) scaffolds was observed over 3 weeks in a SCID/bg aortic interposition model [41]. Long-term results of PLLA-P(CL/LA) TEVG scaffolds seeded with unlabeled hASMCs and hAECs in the SCID/bg aortic interposition...
model demonstrated that the natural history of TEVG development occurs due to rapid mural infiltration by macrophages, late endothelialization, initial dilation of the grafts with PLLA fiber degradation and late contraction, increased collagen deposition with time \textit{in vivo} and increasingly organized tissue architecture approaching that of the native vessel over the course of 1 year (Figure 3) [42]. This chimeric model began to elucidate the process of TEVG maturation as an aortic interposition graft, but required the harvest and \textit{ex vivo} culture of differentiated cells that Shin’oka and colleagues sought to avoid in the first clinical trial [23]. Additionally, the course of dilation and contraction seen in the mouse aortic model has not been observed in our venous studies in mice, sheep or humans.

Meanwhile, the cellular and molecular mechanisms that underpinned the success of the human BM-MNC (hBM-MNC)-seeded scaffolds in the human trial remained unidentified and unexplained. MCP-1, a chemokine involved in monocyte recruitment and angiogenesis, was posited to play a role in graft development [43], so we adapted the small-diameter TEVG IVC mouse model to investigate the role of monocytes and monocyte chemotactic factors in TEVG maturation. In a second chimeric model, PLLA-P(CL/LA) scaffolds seeded with CD14\(^+\)/CD45\(^+\) monocytes isolated from hBM-MNCs were implanted in SCID/bg mice and demonstrated less intimal hyperplasia and were less likely to stenose at 6 months than scaffolds seeded with unfractionated hBM-MNCs or hBM-MNCs excluding monocytes [44]. These results implicated a role for monocytes in maintaining long-term TEVG patency.

CD34\(^+\) hematopoietic stem cells and other potential vascular progenitor cells had been hypothesized to differentiate into the ECs and SMCs of the mature TEVG [28,45]. The monocyte fraction used in the above cell-seeding experiment
excluded human CD34+ hematopoietic stem cells and other potential vascular progenitor cells, yet monocyte-seeded scaffolds gave rise to functional neovessels replete with all vascular lineages (Figure 4) [44]. Immunohistochemical analysis in the chimeric model demonstrated that the ECs and SMCs were of murine origin and that seeded hBM-MNCs did not directly contribute to TEVG neotissue. Moreover, seeded human cells were completely absent from the graft 1 week after implantation. Despite the rapid departure of these cells, hBM-MNC seeding was associated with significantly higher levels of MCP-1 production and enhanced early monocyte recruitment to the scaffold. We investigated the role of MCP-1 in neotissue formation by locally releasing this chemokine from the scaffold. Scaffolds were seeded with MCP-1-releasing alginate microspheres to mimic the presence and action of hBM-MNCs. Local MCP-1 delivery accelerated macrophage infiltration and produced organized neotissue formation similar to hBM-MNC seeding. These experiments suggested that seeded cells enhance patency by releasing cytokines that attract host monocytes to the graft and, more generally, provided the first evidence that seeded cells act in a paracrine fashion to recruit host cells to the TEVG [46].

The evident departure of seeded cells from the developing TEVG raised two more questions: what happens to the seeded cells, and what is the source of the cells that populate the scaffold? To follow seeded cells, we first demonstrated that donor BM-MNCs do not contribute to the host TEVG in immunocompetent C57BL/6 as well as SCID/bg mice. Magnetic resonance tracking of USPIO-labeled murine macrophages seeded on PGA-P(CL/LA) scaffolds showed that seeded macrophages are rapidly lost after implantation and are not incorporated into the TEVG [47].

**Figure 3. Natural history of tissue-engineered vascular graft remodeling by histologic evaluation of the native mouse aorta and tissue-engineered vascular graft at 18 days and 1 year postimplantation.** Native mouse aorta stained with (A) vWF, (B) α-SMA, (C) calponin, (D) Gomori one-step trichrome and (E) Voerhoff–van Gieson. Graft at 18 days postimplantation stained with (F) vWF, (G) α-SMA, (H) calponin, (I) Gomori one-step trichrome and (J) Voerhoff–van Gieson shows formation of luminal endothelial and mural SM cell layers. Graft at 1 year postimplantation stained with (K) vWF, (L) α-SMA, (M) calponin, (N) Gomori one-step trichrome and (O) Voerhoff–van Gieson shows organized trilayer architecture of native aorta (A–E). Original magnification: ×400.

EC: Endothelial cell; SM: Smooth muscle; SMA: Smooth muscle actin; vWF: von Willebrand factor. Reproduced with permission from [42].
We then obtained and harvested bone marrow from inbred transgenic CB57BL/6 mice expressing GFP under the control of the ubiquitin-C promoter. We seeded PLLA-P(CL/LA) scaffolds with GFP-labeled syngeneic mouse BM-MNCs (mBN-MNCs), implanted these grafts into wild-type CB57BL/6 mice, and observed that GFP-labeled donor mBM-MNCs leave the scaffold within 1 week of implantation.

Next, we rescued lethally irradiated wild-type CB57BL/6 female mice with tail vein injection of unfractionated bone marrow from transgenic inbred male CB57BL/6 mice to create a sex-mismatched source of endogenous mBM-MNC. These chimeric females received PLLA-P(CL/LA) scaffolds seeded with unlabeled mBM-MNCs. FISH analysis of grafts explanted at 1 week revealed colocalization of YChr and F4/80+ in cells of the graft wall, demonstrating that host bone marrow-derived macrophages initially populate the scaffold. At 2 weeks, cells positive for vWF and SMA but...
negative for YChr began to appear. At 6 months, the presence of a vWF-YChr endothelial layer and calponin-YChr media confirmed that the TEVG is populated by vascular cells that are not descended from bone marrow-derived vascular progenitors, but from differentiated ECs and SMCs that migrate in from the adjacent anastomosed blood vessels. The few remaining Mac-3-YChr cells confirmed that the early macrophage infiltrate is bone marrow-derived but does not differentiate into vascular phenotypes. Next, we implanted composite vascular grafts made from anastomosed syngeneic male IVC and unseeded TEVG in female CB57BL/6 mice and observed that late ECs and SMCs inhabiting the TEVG segment closest to the male IVC segment stained strongest for YChr. These experiments confirmed that host-derived but not seeded cells contribute to the TEVG cellular population [48].

Finally, we returned to the role of the host macrophage in the development of TEVG stenosis. PLLA-P(CL/LA) scaffolds not seeded or seeded with CB57BL/6 mMB-MNCs were implanted as infrarenal IVC interposition grafts in CB57BL/6 mice. Early stenosis (>50% reduction in luminal diameter on ultrasound) was observed in 80% of unseeded TEVGs and 20% of seeded TEVGs. Critical stenosis only occurred in grafts with early stenosis, and all significant stenosis occurred within 2 weeks of implantation by inward wall thickening with constant outer graft diameter. These outcomes were similar to the observations made in the clinical trial [35] and justify our comparison of the natural history of stenosis in this model to that observed in human TEVG. The extent of macrophage infiltration in the CB57BL/6 model was inversely related to BM-MNC seeding and directly correlated with the degree of TEVG stenosis at the critical 2-week time point. Macrophage phenotype was also related to BM-MNC seeding and the development of stenosis, with M1 expression predominant in seeded scaffolds and M1 to M2 transition evident in unseeded scaffolds, but absent in seeded scaffolds. However, TEVG implants in CD11b-diptheria toxin receptor-transgenic mice, which were depleted of macrophages by intraperitoneal administration of clodronate liposomes, also demonstrated reduced macrophage infiltration, poor endothelialization and stenosis. These results underscore the importance of macrophage infiltration and activation to the in vivo development of our TEVG into a functional vascular conduit. Furthermore, the macrophage activation state observed in this model defies the contested M1/M2 classification of macrophage activation and may represent an as-yet uncharacterized activation phenotype that promotes remodeling of the TEVG [49].

In summary, our clinical and laboratory results thus far demonstrate that the BMC-seeded TEVG has clear clinical potential as a conduit for pediatric CHD and warrants investigation as a conduit for other cardiac and vascular procedures. Limitations of our approach to TEVG fabrication include the necessities of adequate recipient bone marrow and a functional host inflammatory foreign body response, as well as the inefficiencies and poor shelf-life associated with ex vivo cell seeding. Furthermore, bone marrow extraction and seeding significantly increases intraoperative time, and BM-MNC purification requires advanced facilities and techniques. Further study of the cellular and molecular mechanisms of TEVG neotissue formation may lead to the development of a new generation of cell-free, off-the-shelf vascular conduits that could broaden the scope and clinical applications of cardiovascular tissue engineering.

Future perspective

Cytokine release from unseeded TEVG scaffolds can modulate the host response to an implanted TEVG to achieve similar graft phenotypes and patency rate as those attained with cell-seeded grafts [48]. These results have opened a new frontier for cell-free tissue engineering of living vascular grafts. Integration of biomedically engineered drug delivery systems with proven and novel scaffold technologies may allow us to fabricate vascular grafts that elute cytokines and other therapeutics and thereby direct the cellular and molecular processes responsible for neovessel formation. Cell-free TEVGs would eliminate the need for biopsy, ex vivo culture and seeding of recipient cells – existing barriers to the clinical use of TEVGs – and will render autologous vessel harvest unnecessary. Thus, cell-free TEVGs will reduce the number of invasive procedures required to treat a patient with a vascular graft. Further characterization of the natural history of TEVG remodeling will inform the selection of cytokines with which to functionalize TEVG scaffolds. Advances in drug delivery will permit the stable encapsulation of cytokines and facilitate the development of grafts with clinically useful shelf-lives. The era of an off-the-shelf vascular graft that grows with the patient and behaves like a native vessel is clearly in sight.
Executive summary

Single ventricle cardiac anomalies: a significant pediatric health problem
- Congenital heart disease causes significant morbidity and mortality worldwide.
- Single ventricle anomalies are among the most severe of congenital heart diseases, often requiring surgical intervention very early in life.

Currently employed vascular conduits: a limiting factor in the treatment of severe congenital heart disease
- Synthetic conduits used for extracardiac total cavopulmonary connection in the modified Fontan operation are associated with significant morbidity and mortality.
- Tissue engineering promises a nonimmunogenic and thromboresistant vascular graft that is capable of growing with patients.

Evolution of the tissue-engineered vascular conduit: animal studies demonstrating the feasibility of large-caliber tissue-engineered vascular grafts for low-pressure, high-flow applications & our first clinical trials
- Tissue-engineered vascular grafts (TEVGs) created by seeding mature venous cells onto a biodegradable matrix mature in vivo into functional neovessels resembling native vein.
- Autologous human bone marrow cells enriched for the mononuclear fraction (hBM-MNCs) can replace mature vascular cells as a cell source for the TEVG and increase its clinical utility.

Next-generation TEVG: investigating the molecular mechanisms of neotissue formation
- Histological characterization of small-diameter TEVGs in mouse models illuminated the natural history of TEVG maturation.
- Cell seeding with hBM-MNCs accelerates macrophage infiltration and enhances graft cellularity and patency through paracrine signaling.
- Cell-free tissue engineering: local release of MCP-1 from grafts achieves similar outcomes as seeding hBM-MNCs.

Financial & competing interests disclosure
T Shinoka receives partial funding from Gunze, Ltd, a company that makes scaffolds for clinical trials and animal studies. CK Breuer receives partial funding from Pall, Corp. None of the funding for the work described in this manuscript was provided by Gunze, Ltd, or Pall, Corp. The research described was funded by NIH grants (5K08HL083980-05 and 5401HL098228-03). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References
Papers of special note have been highlighted as:
* of interest
** of considerable interest

Tissue-engineered vascular grafts for use in the treatment of congenital heart disease

* Describes the first clinical trial of a tissue-engineered vascular graft (TEVG) for pediatric congenital heart defects.
* Early evidence that TEVG neotissue does not derive from seeded cells.


**Excellent review of the inflammatory and healing processes that influence the development of a TEVG scaffold into a neovessel.**


**Important contribution to the understanding of vascular scaffold remodeling, as well as a proof-of-concept for cytokine release as an alternative to cell seeding.**


**Websites**
